Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Ardizzoni

Showing results (61-70 of 156) with videos related to

Pageof 16
Sort By:
Lung Cancer (Amsterdam, Netherlands)|December 21, 2010
EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutationsM Tiseo, F Gelsomino, D Boggiani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 7, 2017
Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques?F Gelsomino, M Fiorentino, M Zompatori, et al.
International Journal of Immunopathology and Pharmacology|January 10, 2013
Protein microarrays on midtrimester amniotic fluids: a novel approach for the diagnosis of early intrauterine inflammation related to preterm deliveryG B La Sala, A Ardizzoni, F Capodanno, et al.
Cancer Investigation|January 1, 1988
Phase II trial of oral idarubicin in advanced non-small cell lung cancer (NSCLC)A Ardizzoni, P Pronzato, L Repetto, et al.
British Journal of Cancer|December 3, 2009
PTEN status in advanced colorectal cancer treated with cetuximabF V Negri, C Bozzetti, C A Lagrasta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2003
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancerU Gatzemeier, G Groth, C Butts, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Thymidine labelling index as prognostic factor in resected non-small cell lung cancerA Alama, M Costantini, L Repetto, et al.
Anticancer Research|July 1, 1989
Oral chemotherapy for poor risk small-cell lung cancer patients with combined idarubicin and etoposideA Ardizzoni, C Pennucci, V Fusco, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
Phase II study of ACNU as second-line treatment in small-cell lung cancer. EORTC Lung Cancer Cooperative GroupA S Planting, T A Splinter, A Ardizzoni, et al.
Lung Cancer (Amsterdam, Netherlands)|February 13, 2001
Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patientsB Castagneto, S Zai, L Mutti, et al.
Pageof 16

Showing results (61-70 of 156) with videos related to

Sort By:
Pageof 16
Lung Cancer (Amsterdam, Netherlands)|December 21, 2010
EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutationsM Tiseo, F Gelsomino, D Boggiani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 7, 2017
Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques?F Gelsomino, M Fiorentino, M Zompatori, et al.
International Journal of Immunopathology and Pharmacology|January 10, 2013
Protein microarrays on midtrimester amniotic fluids: a novel approach for the diagnosis of early intrauterine inflammation related to preterm deliveryG B La Sala, A Ardizzoni, F Capodanno, et al.
Cancer Investigation|January 1, 1988
Phase II trial of oral idarubicin in advanced non-small cell lung cancer (NSCLC)A Ardizzoni, P Pronzato, L Repetto, et al.
British Journal of Cancer|December 3, 2009
PTEN status in advanced colorectal cancer treated with cetuximabF V Negri, C Bozzetti, C A Lagrasta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2003
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancerU Gatzemeier, G Groth, C Butts, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Thymidine labelling index as prognostic factor in resected non-small cell lung cancerA Alama, M Costantini, L Repetto, et al.
Anticancer Research|July 1, 1989
Oral chemotherapy for poor risk small-cell lung cancer patients with combined idarubicin and etoposideA Ardizzoni, C Pennucci, V Fusco, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
Phase II study of ACNU as second-line treatment in small-cell lung cancer. EORTC Lung Cancer Cooperative GroupA S Planting, T A Splinter, A Ardizzoni, et al.
Lung Cancer (Amsterdam, Netherlands)|February 13, 2001
Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patientsB Castagneto, S Zai, L Mutti, et al.
Pageof 16